RhumbLine Advisers
AMLX icon

RhumbLine Advisers’s Amylyx Pharmaceuticals AMLX Stock Holding History

RhumbLine Advisers’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.03M Buy
112,920
+4,453
+4% +$68.9K ﹤0.01% 1927
2026
Q1 		$1.51M Buy
108,467
+9,193
+9% +$129K ﹤0.01% 2007
2025
Q4 		$1.2M Buy
99,274
+617
+0.6% +$8.38K ﹤0.01% 2137
2025
Q3 		$1.34M Sell
98,657
-1,919
-2% -$18.1K ﹤0.01% 2099
2025
Q2 		$645K Buy
+100,576
New +$489K ﹤0.01% 2508
2024
Q3 		– Sell
-28,779
Closed -$54.7K – 4199
2024
Q2 		$54.7K Sell
28,779
-40,624
-59% -$78.7K ﹤0.01% 3658
2024
Q1 		$197K Buy
69,403
+1,120
+2% +$14.6K ﹤0.01% 3188
2023
Q4 		$1.01M Sell
68,283
-677
-1% -$10.4K ﹤0.01% 2249
2023
Q3 		$1.26M Buy
68,960
+865
+1% +$18.3K ﹤0.01% 2082
2023
Q2 		$1.47M Sell
68,095
-7,867
-10% -$212K ﹤0.01% 2084
2023
Q1 		$2.23M Buy
75,962
+4,398
+6% +$153K ﹤0.01% 1750
2022
Q4 		$2.64M Buy
71,564
+25,771
+56% +$915K ﹤0.01% 1635
2022
Q3 		$1.29M Buy
45,793
+29,619
+183% +$739K ﹤0.01% 2007
2022
Q2 		$312K Buy
+16,174
New +$192K ﹤0.01% 2732

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

RhumbLine Advisers's AMLX Position: Q2 2026 in Review

RhumbLine Advisers increased its Amylyx Pharmaceuticals (AMLX) stake by 4.1% in Q2 2026, buying an estimated $68.9K and bringing the position to 112,920 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1927.

RhumbLine Advisers first reported a position in AMLX in Q2 2022 and has held it in 14 quarters since. The position peaked at $2.64M in Q4 2022. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • RhumbLine Advisers held 112,920 shares of Amylyx Pharmaceuticals worth $2.03M as of Q2 2026.
  • RhumbLine Advisers bought 4,453 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $68.9K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1927 holding.
  • RhumbLine Advisers first reported a position in Amylyx Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
  • RhumbLine Advisers's Amylyx Pharmaceuticals position peaked at $2.64M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.